Study: NCT03696459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678, 2000 mg
Description: Participants will be administered JNJ-53718678, 2000 mg as oral suspension in Part 1 (Panel 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678, 3000 mg
Description: Participants will be administered JNJ- 53718678, 3000 mg as oral suspension in Part 1 (Panel 2).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678, 4500 mg or Dose to be decided
Description: Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678, 4500 mg or Dose to be decided
Description: Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678, 4500 mg or Dose to be decided
Description: Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678, 4500 mg or Dose to be decided
Description: Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678, 4500 mg or Dose to be decided
Description: Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678, 4500 mg or Dose to be decided
Description: Participants will be administered JNJ-53718678, 4500 mg as oral suspension in Part 1 (Panel 3). If this dose is considered safe and tolerable and if pharmacokinetic data require further dose escalation, then participants will receive JNJ-53718678 (Dose to be decided) in Part 1 (Panel 4). This dose (either from Panel 3 or Panel 4 ) will be used in Part 2 (Dose may be lower/higher based on review of safety, tolerability, and PK data obtained in Part 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 500 mg
Description: Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 500 mg
Description: Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 500 mg
Description: Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 500 mg
Description: Participants will be administered JNJ-53718678, 500 mg as oral suspension in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 Placebo
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 Placebo
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 Placebo
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 Placebo
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 Placebo
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 Placebo
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 Placebo
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678 Placebo
Description: Participants will be administered JNJ-53718678 matching placebo in Part 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Participants will be administered moxifloxacin 400 mg as capsule in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Participants will be administered moxifloxacin 400 mg as capsule in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Participants will be administered moxifloxacin 400 mg as capsule in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg
Description: Participants will be administered moxifloxacin 400 mg as capsule in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Participants will be administered moxifloxacin matching placebo in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Participants will be administered moxifloxacin matching placebo in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Participants will be administered moxifloxacin matching placebo in Part 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Placebo
Description: Participants will be administered moxifloxacin matching placebo in Part 2.